Search research articles
Contact Us
Filters
Showing results (71-80 of 172) with videos related to
Page
of 18
Sort By:
Annals of the Rheumatic Diseases
|
August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
RMD Open
|
January 21, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
Josef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, et al.
Arthritis Research & Therapy
|
June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
Mark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
The Journal of Rheumatology
|
July 5, 2005
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
Mark C Genovese, Joan M Bathon, Roy M Fleischmann, et al.
The Journal of Rheumatology
|
April 21, 2007
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
Mark C Genovese, Philip J Mease, Glen T D Thomson, et al.
The Journal of Rheumatology
|
February 3, 2011
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis
Mark C Genovese, Stanley B Cohen, David Wofsy, et al.
Arthritis and Rheumatism
|
September 30, 2008
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
Mark C Genovese, James D McKay, Evgeny L Nasonov, et al.
Arthritis Care & Research
|
October 26, 2012
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study
Peter Nash, Sauithree Nayiager, Mark C Genovese, et al.
The Journal of Rheumatology
|
January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, et al.
The Journal of Rheumatology
|
March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
Mark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.
Page
of 18
Search research articles
Search
Showing results (71-80 of 172) with videos related to
Sort By:
Page
of 18
Annals of the Rheumatic Diseases
|
August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
RMD Open
|
January 21, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
Josef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, et al.
Arthritis Research & Therapy
|
June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
Mark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
The Journal of Rheumatology
|
July 5, 2005
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
Mark C Genovese, Joan M Bathon, Roy M Fleischmann, et al.
The Journal of Rheumatology
|
April 21, 2007
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
Mark C Genovese, Philip J Mease, Glen T D Thomson, et al.
The Journal of Rheumatology
|
February 3, 2011
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis
Mark C Genovese, Stanley B Cohen, David Wofsy, et al.
Arthritis and Rheumatism
|
September 30, 2008
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
Mark C Genovese, James D McKay, Evgeny L Nasonov, et al.
Arthritis Care & Research
|
October 26, 2012
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study
Peter Nash, Sauithree Nayiager, Mark C Genovese, et al.
The Journal of Rheumatology
|
January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, et al.
The Journal of Rheumatology
|
March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
Mark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.
Page
of 18